Association of metabolic syndrome and hidradenitis suppurativa.

IMPORTANCE An association between the metabolic syndrome (MetS) and chronic inflammatory diseases, such as psoriasis or rheumatoid arthritis, has been suggested.Hidradenitis suppurativa (HS), a more localized chronic inflammation of the skin, has been speculated to have a similar association. Hidradenitis suppurativa is a substantial burden for the individual and a socioeconomic burden globally. Information about the burden of possible comorbidities is scarce.OBJECTIVE To investigate the possibility of an association between HS and MetS.DESIGN, SETTING, AND PARTICIPANTS Cross-sectional population- and hospital-based study of HS and MetS.We identified 32 patients with physician-verified HS from the outpatient clinic at the Department of Dermatology, Roskilde Hospital, and 326 patients with HS and 14 851 individuals without HS from the general population. Individuals with HS were younger,predominantly female, and more often smokers compared with the non-HS group.EXPOSURE Hidradenitis suppurativa.MAIN OUTCOMES AND MEASURES Metabolic syndrome and its components of diabetes mellitus, hypertension, dyslipidemia, and obesity.RESULTS When compared with the non-HS group, the odds ratios (ORs) for the hospital HS and population HS groups were 3.89 (95%CI, 1.90-7.98) and 2.08 (95%CI, 1.61-2.69),respectively, for MetS; 5.74 (95%CI, 1.91-17.24) and 2.44 (95%CI, 1.55-3.83), respectively, for diabetes mellitus; 6.38 (95%CI, 2.99-13.62) and 2.56 (95%CI, 2.00-3.28), respectively, for general obesity; and 3.62 (95%CI, 1.73-7.60) and 2.24 (95%CI, 1.78-2.82), respectively, for abdominal obesity. With regard to dyslipidemia, significant results were found for decreased levels of high-density lipoprotein cholesterol, with ORs of 2.97 (95%CI, 1.45-6.08) and 1.94(95%CI, 1.52-2.48) for the hospital HS and general population HS groups, respectively, when compared with the non-HS group. With regard to increased triglyceride levels, only the result for the population HS group compared with the non-HS group was significant, with an OR of1.49 (95%CI, 1.18-1.87). The OR for hypertension, which was only significant for the hospital HS group compared with the non-HS group, was 2.14 (95%CI, 1.01-4.53). Obesity and inflammation acted as possible confounders. The ORs were higher for the hospital HS group compared with the population HS group. The association between HS and MetS was not influenced by the degree of HS severity.CONCLUSIONS AND RELEVANCE As with more systemic inflammatory diseases, HS appears to be associated with MetS, indicating substantial comorbidities. Because this study is cross-sectional, causality remains to be explored.

[1]  G. Jemec,et al.  The prevalence of inverse recurrent suppuration: a population‐based study of possible hidradenitis suppurativa , 2014, The British journal of dermatology.

[2]  I. Hamzavi,et al.  The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. , 2014, Journal of the American Academy of Dermatology.

[3]  T. Skaaby,et al.  Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta‐analysis , 2013, The British journal of dermatology.

[4]  G. Jemec,et al.  Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. , 2013, Journal of the American Academy of Dermatology.

[5]  R. Verdolini,et al.  Metformin for the treatment of hidradenitis suppurativa: a little help along the way , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  B. Nordestgaard,et al.  Study design, participation and characteristics of the Danish General Suburban Population Study. , 2013, Danish medical journal.

[7]  P. Wolkenstein,et al.  Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. , 2013, The Journal of investigative dermatology.

[8]  P. Stang,et al.  Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. , 2013, Journal of the American Academy of Dermatology.

[9]  M. González-Gay,et al.  Metabolic Syndrome in Rheumatoid Arthritis , 2013, Mediators of inflammation.

[10]  T. Russo,et al.  The heliotrope sign of dermatomyositis: the correct meaning of the term heliotrope. , 2012, Archives of dermatology.

[11]  G. Kokolakis,et al.  Increased Prevalence of Metabolic Syndrome in Patients with Acne Inversa , 2012, PloS one.

[12]  G. Jemec Clinical practice. Hidradenitis suppurativa. , 2012, The New England journal of medicine.

[13]  H. Partsch,et al.  Reticulate eruptions: Part 2. Historical perspectives, morphology, terminology and classification , 2011, The Australasian journal of dermatology.

[14]  R. MacIsaac,et al.  Intensive glucose control and cardiovascular outcomes in type 2 diabetes. , 2011, Heart, lung & circulation.

[15]  G. Jemec,et al.  Psychosocial impact of hidradenitis suppurativa: a qualitative study. , 2011, Acta dermato-venereologica.

[16]  J. Szepietowski,et al.  Psychophysical aspects of hidradenitis suppurativa. , 2010, Acta dermato-venereologica.

[17]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[18]  J. Shaw,et al.  International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes , 2009, Diabetes Care.

[19]  N J Wald,et al.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.

[20]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[21]  B. Nordestgaard,et al.  Fasting and Nonfasting Lipid Levels: Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction , 2008, Circulation.

[22]  O. Faye,et al.  Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. , 2008, Journal of the American Academy of Dermatology.

[23]  H. Kurzen,et al.  What causes hidradenitis suppurativa? , 2008, Experimental dermatology.

[24]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Circulation.

[25]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[26]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[27]  J. Lapins,et al.  Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa , 2003, The British journal of dermatology.

[28]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[29]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[30]  H. Williams,et al.  The natural history of hidradenitis suppurativa , 2000, Journal of the European Academy of Dermatology and Venereology : JEADV.

[31]  G. Jemec,et al.  Hidradenitis suppurativa ‐ characteristics and consequences , 1996, Clinical and experimental dermatology.

[32]  G. Jemec,et al.  The prevalence of hidradenitis suppurativa and its potential precursor lesions. , 1996, Journal of the American Academy of Dermatology.

[33]  A. Weaver,et al.  Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. , 2013, The Journal of investigative dermatology.

[34]  G. Jemec,et al.  Maturation of an Idea: A Historical Perspective on the Association of Psoriasis With the Metabolic Syndrome and Cardiovascular Disease , 2012 .

[35]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[36]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.